Alpha 2.0
Login Register
» Articles » PMID: 38577056

A Case of Dupilumab-induced Psoriasis-like Eruption Treated with Baricitinib

Overview
Journal Skin Health Dis
Publisher Oxford University Press
Specialty Dermatology
Date 2024 Apr 5
PMID 38577056
Authors
Yuki Kinoshita
Hisayoshi Imanishi
Tomoko Oshimo
Daisuke Tsuruta
Affiliations
Soon will be listed here.
Abstract

Dupilumab is a humanized monoclonal antibody against the interleukin (IL)-4 receptor alpha chain that inhibits IL-4 and IL-13 signalling. It is one of the systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), which provides favourable safety and efficacy. We report a case of psoriasis-like eruption induced by dupilumab as an adverse effect in a patient with AD, immediately remitted after switching to baricitinib, which inhibits JAK1/2. Moreover, the atopic skin lesion also simultaneously went into remission upon baricitinib treatment. Baricitinib could be a favourable option for patients with AD who develop dupilumab-induced psoriasis-like eruption.

Citing Articles

Human Beta Defensin-2 mRNA and Proteasome Subunit β Type 8 mRNA Analysis, Useful in Differentiating Skin Biopsies from Atopic Dermatitis and Psoriasis Vulgaris Patients.

Terlikowska-Brzosko A, Galus R, Murawski P, Niderla-Bielinska J, Mlynarczuk-Bialy I, Paluchowska E Int J Mol Sci. 2024; 25(17).

PMID: 39273140 PMC: 11395582. DOI: 10.3390/ijms25179192.

A case of dupilumab-induced psoriasis-like eruption treated with baricitinib.

Kinoshita Y, Imanishi H, Oshimo T, Tsuruta D Skin Health Dis. 2024; 4(2):e338.

PMID: 38577056 PMC: 10988729. DOI: 10.1002/ski2.338.

References
1.
Ali K, Wu L, Qiu Y, Li M . Case report: Clinical and histopathological characteristics of psoriasiform erythema and IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab. Front Med (Lausanne). 2022; 9:932766. PMC: 9366075. DOI: 10.3389/fmed.2022.932766. View
2.
Safa G, Paumier V . Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019; 44(3):e49-e50. DOI: 10.1111/ced.13901. View
3.
Kinoshita Y, Imanishi H, Oshimo T, Tsuruta D . A case of dupilumab-induced psoriasis-like eruption treated with baricitinib. Skin Health Dis. 2024; 4(2):e338. PMC: 10988729. DOI: 10.1002/ski2.338. View
4.
Tracey E, Elston C, Feasel P, Piliang M, Michael M, Vij A . Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018; 4(7):708-710. PMC: 6098196. DOI: 10.1016/j.jdcr.2018.05.014. View
5.
Ferrucci S, Buffon S, Marzano A, Maronese C . Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib. Clin Exp Dermatol. 2022; 47(5):986-987. DOI: 10.1111/ced.15104. View